89bio Inc (ETNB)
8.88
+0.13
(+1.49%)
USD |
NASDAQ |
May 02, 16:00
8.885
0.00 (0.00%)
After-Hours: 18:09
89bio Cash from Financing (TTM): 513.11M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 513.11M |
September 30, 2023 | 371.95M |
June 30, 2023 | 442.06M |
March 31, 2023 | 439.46M |
December 31, 2022 | 117.83M |
September 30, 2022 | 118.71M |
June 30, 2022 | 50.15M |
March 31, 2022 | 23.68M |
December 31, 2021 | 23.87M |
Date | Value |
---|---|
September 30, 2021 | 1.668M |
June 30, 2021 | 159.89M |
March 31, 2021 | 158.13M |
December 31, 2020 | 157.92M |
September 30, 2020 | 246.61M |
June 30, 2020 | 88.81M |
March 31, 2020 | 107.71M |
December 31, 2019 | 107.70M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
1.668M
Minimum
Sep 2021
513.11M
Maximum
Dec 2023
184.08M
Average
118.71M
Median
Sep 2022
Cash from Financing (TTM) Benchmarks
Madrigal Pharmaceuticals Inc | 595.12M |
Akero Therapeutics Inc | 353.32M |
Viking Therapeutics Inc | 873.23M |
Galectin Therapeutics Inc | 40.03M |
Terns Pharmaceuticals Inc | 41.95M |